Matches in DBpedia 2016-04 for { <http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020471s017lbl.pdf> ?p ?o }
Showing triples 1 to 12 of
12
with 100 triples per page.
- 020471s017lbl.pdf accessdate "2014-12-12".
- 020471s017lbl.pdf date "June 2012".
- 020471s017lbl.pdf isCitedBy Antileukotriene.
- 020471s017lbl.pdf isCitedBy Arachidonate_5-lipoxygenase_inhibitor.
- 020471s017lbl.pdf isCitedBy Asthma.
- 020471s017lbl.pdf page "1".
- 020471s017lbl.pdf publisher "Cornerstone Therapeutics Inc.".
- 020471s017lbl.pdf quote "Zileuton is a specific inhibitor of 5-lipoxygenase and thus inhibits leukotriene formation. Both the R and S enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Sulfido-peptide leukotrienes and LTB4, a chemoattractant for neutrophils and eosinophils, can be measured in a number of biological fluids including bronchoalveolar lavage fluid from asthmatic patients.".
- 020471s017lbl.pdf title "Zyflo".
- 020471s017lbl.pdf url 020471s017lbl.pdf.
- 020471s017lbl.pdf url "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020471s017lbl.pdf".
- 020471s017lbl.pdf website "United States Food and Drug Administration".